Abstract: The present disclosure relates to hybrid hepadnavirus core antigens including one or more epitopes of a human hepatitis B vims (HBV) antigen. More specifically, the present disclosure relates to hybrid hepadnavirus core antigens in the form of fusion proteins containing a fragment of the PreS1 region of the HBV surface antigen inserted in a woodchuck hepadnavirus core antigen. The present disclosure further relates to hybrid hepadnavirus core antigens in the form of fusions proteins containing a truncated HBV core antigen and woodchuck hepadnavirus core antigen. Also provided are nucleic acids encoding the hybrid core antigens, and the use of the hybrid core antigens and nucleic acids for treating HBV-infected individuals.

Abstract: The present disclosure relates to rodent hepadnavirus core antigens including one or more B cell and T cell epitopes of a malaria parasite antigen. More specifically, the present disclosure relates to hybrid woodchuck hepadnavirus core antigens that have been modified to diminish the antibody response to the core antigen so as to enhance the antibody response to fragments of malaria antigen(s) included therein.

Abstract: The present disclosure relates to rodent hepadnavirus core antigens including one or more B cell and T cell epitopes of a malaria parasite antigen. More specifically, the present disclosure relates to hybrid woodchuck hepadnavirus core antigens that have been modified to diminish the antibody response to the core antigen so as to enhance the antibody response to fragments of malaria antigen(s) included therein.

Abstract: The present disclosure generally relates to hepadnavirus core antigens in which one or more endogenous b cell epitopes have been effectively removed. More specifically, the present disclosure relates to rodent hepadnavirus cores modified to diminish the antibody response to the core so as to enhance the antibody response to heterologous polypeptides included therein.

Abstract: The present disclosure generally relates to immunogens for eliciting an antibody response against respiratory syncytial virus (RSV). More specifically, the present disclosure relates to virus-like particles (VLPs) including a RSV F protein epitope, as well as methods of use thereof. Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in infants and young children (Hall et al., NEJM, 360:5888-598, 2009; and Nair et al., Lancet, 375:1545-1555, 2010) and a vaccine to protect this young population is of high priority.

Abstract: The present disclosure generally relates to hepadnavirus core antigens in which one or more endogenous b cell epitopes have been effectively removed. More specifically, the present disclosure relates to rodent hepadnavirus cores modified to diminish the antibody response to the core so as to enhance the antibody response to heterologous polypeptides included therein.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated.

Abstract: The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations.

Abstract: The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated.

Abstract: Human antibodies that bind to woodchuck hepatitis virus core antigen are elevated in chronic hepatitis B patients in comparison to acute hepatitis B patients. Immunoassays for detection of the level of anti-WHV core antigen antibodies is used to distinguish chronic from acute hepatitis B patients.

Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.

Abstract: Polypeptides corresponding in amino acid residue sequence to T cell stimulating regions of the HBV nucleocapsid protein are disclosed. A method of enhancing the immunogenicity of a polypeptide immunogen comprising operatively linking the polypeptide through an amino acid residue side chain to core protein particles is also disclosed.